Terns Pharmaceuticals, Inc. (FRA:430)

Market Cap	3.62B +853.2%
Revenue (ttm)	n/a
Net Income	-80.49M
EPS	-0.88
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	153
Open	33.20
Previous Close	33.20
Day's Range	32.60 - 33.40
52-Week Range	1.70 - 39.80
Beta	n/a
RSI	56.68
Earnings Date	Mar 23, 2026

About Terns Pharmaceuticals

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in Phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of metabolic ...

• Industry: Pharmaceutical Preparations
• Founded: 2016
• Employees: 59
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 430

Financial Performance

Financial numbers in USD